Overexpression of high mobility group protein B1 correlates with the proliferation and metastasis of lung adenocarcinoma cells

Molecular Medicine Reports

Volumn 7, Issue 5, 2013, Pages 1678-1682

  Sun, Ke Kang ^a   Ji, Cheng ^b   Li, Xing ^a   Zhang, Lu ^a   Deng, Jun ^a   Zhong, Ning ^a   Wu, Xiao Yang ^a  

^a KUNSHAN FIRST PEOPLE S HOSPITAL AFFILIATED TO JIANGSU UNIVERSITY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

Author keywords

Angiogenesis; High mobility group protein B1; Lung cancer; Metastasis; Mitogen activated protein kinase

Indexed keywords

HIGH MOBILITY GROUP B1 PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38;

ARTICLE; CANCER INVASION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG ADENOCARCINOMA; LUNG CARCINOGENESIS; LUNG METASTASIS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADENOCARCINOMA; CELL LINE, TUMOR; CELL PROLIFERATION; ENZYME ACTIVATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENE EXPRESSION REGULATION, NEOPLASTIC; HMGB1 PROTEIN; HUMANS; LUNG NEOPLASMS; MAP KINASE SIGNALING SYSTEM; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; P38 MITOGEN-ACTIVATED PROTEIN KINASES;

EID: 84876006961     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2013.1362     Document Type: Article

References (18)

1. Jemal A, Bray F, Center MM, et al: Global cancer statistics. CA Cancer J Clin 2: 69-90, 2011.
2. Singhal S, Miller D, Ramalingam S and Sun SY: Gene expression profiling of non-small cell lung cancer. Lung Cancer 60: 313-324, 2008.
3. Li C, Fan S, Owonikoko TK, et al: Oncogenic role of EAPII in lung cancer development and its activation of the MAPK-ERK pathway. Oncogene 35: 3802-3812, 2011.
4. Larsen JE, Cascone T, Gerber DE, et al: Targeted therapies for lung cancer. Cancer J 6: 512-527, 2011.
5. Lotze MT and Tracey KJ: High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol 5: 331-342, 2005.
6. Muller S, Scaffidi P, Degryse B, et al: New EMBO members' review: the double life of HMGB1 chromatin protein: architectural factor and extracellular signal. EMBO J 20: 4337-4340, 2001.
7. Tang DL, Kang R, Zeh HR III and Lotze MT: High-mobility group box 1 and cancer. Biochim Biophys Acta 1799: 131-140, 2010.
8. Lotze MT and DeMarco RA: Dealing with death: HMGB1 as a novel target for cancer therapy. Curr Opin Investig Drugs 4: 1405-1409, 2003.
9. Ito I, Fukazawa J and Yoshida M: Post-translational methylation of high mobility group box 1 (HMGB1) causes its cytoplasmic localization in neutrophils. J Biol Chem 282: 16336-16344, 2007.
10. Taguchi A, Blood DC, del Toro G, et al: Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature 405: 354-360, 2000.
11. Jiao Y, Wang HC and Fan SJ: Growth suppression and radiosensitivity increase by HMGB1 in breast cancer. Acta Pharmacol Sin 28: 1957-1967, 2007.
12. Li XL, Meng QH and Fan SJ: Adenovirus-mediated expression of UHRF1 reduces the radiosensitivity of cervical cancer HeLa cells to gamma-irradiation. Acta Pharmacol Sin 30: 458-466, 2009.
13. Wu QF, Liu C, Tai MH, et al: Knockdown of FoxM1 by siRNA interference decreases cell proliferation, induces cell cycle arrest and inhibits cell invasion in MHCC-97H cells in vitro. Acta Pharmacol Sin 31: 361-366, 2010.
14. Jiao Y, Ge CM, Meng QH, et al: Adenovirus-mediated expression of Tob1 sensitizes breast cancer cells to ionizing radiation. Acta Pharmacol Sin 28: 1628-1636, 2007.
15. Jiao Y, Ge CM, Meng QH, et al: Dihydroartemisinin is an inhibitor of ovarian cancer cell growth. Acta Pharmacol Sin 28: 1045-1056, 2007.
16. Jiang R, Wang NP, Tanaka KA, et al: Factor Xa induces tissue factor expression in endothelial cells by P44/42 MAPK and NF-κB-dependent pathways. J Surg Res 169: 319-327, 2011.
17. Ray MR, David J and He B: Lung cancer therapeutics that target signaling pathways: an update. Expert Rev Respir Med 4: 631-645, 2010.
18. Palmer RH, Vernersson E, Grabbe C and Hallberg B: Anaplastic lymphoma kinase: signalling in development and disease. Biochem J 420: 345-361, 2009.